Epitranscriptomic Remodeling of N6-Methyladenosine (m6A) RNA Marks in CRISPR-Edited Genomes: Emerging Implications for Off-Target Genetic Instability and Precision Gene Therapy
Keywords:
Epitranscriptomics, N6-methyladenosine (m6A), CRISPR-Cas9, Genome Editing, RNA Modification, Off-target Effects, DNA Damage Response, Precision Gene TherapyAbstract
With the advent of epitranscriptomics, there is the addition of a regulatory layer of control over gene expression which goes beyond DNA sequence and chromatin-based regulation and encompasses dynamic chemical RNA modification. Of these N6-methyladenosine (m6A) is the most common interior modification of eukaryotic messenger RNA (mRNA) and is crucial in maintaining RNA stability, splicing, nuclear export, and translational efficiency. M6A deposition, removal and functional interpretation are regulated by an extensive system of methyltransferases (writers), demethylases (erasers) and RNA-binding proteins (readers), which allow a rapid and reversible regulation of gene expression in response to cellular signals.
Simultaneously, the emergence of CRISPR-Cas genome editing technologies has transformed the field of molecular biology and provided a new opportunity in the field of precision gene therapy. Although significant focus has been placed on the conceptualization of off-target DNA mutation and genomic instability, the consequences of genome editing on RNA layers of control, and especially, the epitranscriptomic changes have not been fully investigated. Recent data indicate that, following the formation of CRISPR-induced DNA double-strand breaks and the ensuing activation of DNA damage response pathways, the global state of cells can be changed, with a potential impact on m6A deposition patterns, including: chromatin remodeling, transcriptional reprogramming, and stress signaling.
This review offers the highest possible idea of the m6A epitranscriptomic environment and its regulatory apparatus, and then a deeper discussion of CRISPR-Cas systems and the cellular reactions related to it. We make the mechanistic case of the interaction between genome editing and m6A remodelling, and how the transcriptional dynamics and RNA-binding protein activity perturbation can cause transcriptome-wide changes in m6A distribution. We also compare the existing methods of m6A modifications detection, their advantages, and shortcomings, and address their possibilities of use in CRISPR-based research.
Notably, we discuss the consequences of the CRISPR-based epitranscriptomic variability to precise gene therapy, in which unintended RNA-level regulatory alterations can influence treatment safety, efficacy and reproducibility. Combining the findings of RNA biology, genome engineering, and high-throughput sequencing technologies, this review highlights the importance of taking into consideration epitranscriptomic measurements in genome editing models. The interaction between the CRISPR systems and m6A regulation will need a better insight, as it will be the key to more precise and safer therapeutic approaches.
References
Dominissini, D.; Moshitch-Moshkovitz, S.; Schwartz, S.; Salmon-Divon, M.; Ungar, L.; Osenberg, S.; Cesarkas, K.; Jacob-Hirsch, J.; Amariglio, N.; Kupiec, M.; et al. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature 2012, 485, 201–206. [Google Scholar] [CrossRef] [PubMed]
He, P.C.; He, C. m6A RNA methylation: From mechanisms to therapeutic potential. EMBO J. 2021, 40, e105977. [Google Scholar] [CrossRef] [PubMed]
Cusenza, V.Y.; Tameni, A.; Neri, A.; Frazzi, R. The lncRNA epigenetics: The significance of m6A and m5C lncRNA modifications in cancer. Front. Oncol. 2023, 13, 1063636. [Google Scholar] [CrossRef] [PubMed]
Wang, J.; Wang, L. Deep analysis of RNA N6-adenosine methylation (m6A) patterns in human cells. NAR Genom. Bioinform. 2020, 2, lqaa007. [Google Scholar] [CrossRef]
Yang, S.; Wei, J.; Cui, Y.H.; Park, G.; Shah, P.; Deng, Y.; Aplin, A.E.; Lu, Z.; Hwang, S.; He, C.; et al. m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade. Nat. Commun. 2019, 10, 2782. [Google Scholar] [CrossRef]
Shi, Y.; Fan, S.; Wu, M.; Zuo, Z.; Li, X.; Jiang, L.; Shen, Q.; Xu, P.; Zeng, L.; Zhou, Y.; et al. YTHDF1 links hypoxia adaptation and non-small cell lung cancer progression. Nat. Commun. 2019, 10, 4892. [Google Scholar] [CrossRef]
Han, M.; Liu, Z.; Xu, Y.; Liu, X.; Wang, D.; Li, F.; Wang, Y.; Bi, J. Abnormality of m6A mRNA Methylation Is Involved in Alzheimer’s Disease. Front. Neurosci. 2020, 14, 98. [Google Scholar] [CrossRef]
Dorn, L.E.; Lasman, L.; Chen, J.; Xu, X.; Hund, T.J.; Medvedovic, M.; Hanna, J.H.; van Berlo, J.H.; Accornero, F. The N-Methyladenosine mRNA Methylase METTL3 Controls Cardiac Homeostasis and Hypertrophy. Circulation 2019, 139, 533–545. [Google Scholar] [CrossRef]
Wang, H.; Hu, X.; Huang, M.; Liu, J.; Gu, Y.; Ma, L.; Zhou, Q.; Cao, X. Mettl3-mediated mRNA m6A methylation promotes dendritic cell activation. Nat. Commun. 2019, 10, 1898. [Google Scholar] [CrossRef]
Zhang, Y.; Wang, X.; Zhang, X.; Wang, J.; Ma, V.; Zhang, L.; Cao, X. RNA-binding protein YTHDF3 suppresses interferon-dependent antiviral responses by promoting FOXO3 translation. Proc. Natl. Acad. Sci. USA 2019, 116, 976–981. [Google Scholar] [CrossRef]
Liu, J.; Yue, Y.; Han, D.; Wang, X.; Fu, Y.; Zhang, L.; Jia, G.; Yu, M.; Lu, Z.; Deng, X.; et al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat. Chem. Biol. 2014, 10, 93–95. [Google Scholar] [CrossRef]
Bokar, J.A.; Rath-Shambaugh, M.E.; Ludwiczak, R.; Narayan, P.; Rottman, F. Characterization and partial purification of mRNA N6-adenosine methyltransferase from HeLa cell nuclei: Internal mRNA methylation requires a multisubunit complex. J. Biol. Chem. 1994, 269, 17697–17704. [Google Scholar] [CrossRef]
Theler, D.; Dominguez, C.; Blatter, M.; Boudet, J.; Allain, F.H.T. Solution structure of the YTH domain in complex with N6-methyladenosine RNA: A reader of methylated RNA. Nucleic Acids Res. 2014, 42, 13911–13919. [Google Scholar] [CrossRef]
Rauch, S.; He, C.; Dickinson, B.C. Targeted m6A reader proteins to study epitranscriptomic regulation of single RNAs. J. Am. Chem. Soc. 2018, 140, 11974–11981. [Google Scholar] [CrossRef] [PubMed]
Sokpor, G.; Xie, Y.; Nguyen, H.P.; Tuoc, T. Emerging Role of m6 A Methylome in Brain Development: Implications for Neurological Disorders and Potential Treatment. Front. Cell Dev. Biol. 2021, 9, 656849. [Google Scholar] [CrossRef] [PubMed]
Huang, H.; Weng, H.; Sun, W.; Qin, X.; Shi, H.; Wu, H.; Zhao, B.S.; Mesquita, A.; Liu, C.; Yuan, C.L.; et al. Recognition of RNA N(6)-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat. Cell Biol. 2018, 20, 285–295. [Google Scholar] [CrossRef] [PubMed]
Mauer, J.; Sindelar, M.; Despic, V.; Guez, T.; Hawley, B.R.; Vasseur, J.J.; Rentmeister, A.; Gross, S.S.; Pellizzoni, L.; Debart, F.; et al. FTO controls reversible m6Am RNA methylation during snRNA biogenesis. Nat. Chem. Biol. 2019, 15, 340–347. [Google Scholar] [CrossRef]
Ke, S.; Alemu, E.A.; Mertens, C.; Gantman, E.C.; Fak, J.J.; Mele, A.; Haripal, B.; Zucker-Scharff, I.; Moore, M.J.; Park, C.Y.; et al. A majority of m6A residues are in the last exons, allowing the potential for 3’ UTR regulation. Genes Dev. 2015, 29, 2037–2053. [Google Scholar] [CrossRef]
Zhang, W.; Qian, Y.; Jia, G. The detection and functions of RNA modification m6A based on m6A writers and erasers. J. Biol. Chem. 2021, 297, 100973. [Google Scholar] [CrossRef]
Kostyusheva, A.; Brezgin, S.; Glebe, D.; Kostyushev, D.; Chulanov, V. Host-cell interactions in HBV infection and pathogenesis: The emerging role of m6A modification. Emerg. Microbes Infect. 2021, 10, 2264–2275. [Google Scholar] [CrossRef]
Hu, L.; Liu, S.; Peng, Y.; Ge, R.; Su, R.; Senevirathne, C.; Harada, B.T.; Dai, Q.; Wei, J.; Zhang, L.; et al. m6A RNA modifications are measured at single-base resolution across the mammalian transcriptome. Nat. Biotechnol. 2022, 40, 1210–1219. [Google Scholar]
Zhang, Q.; Dai, Y.; Teng, X.; Li, J. Visualization and Quantification of Single-Base m6A Methylation. Angew. Chem. Int. Ed. Engl. 2025, 64, e202420977. [Google Scholar] [CrossRef]
Liu, Z.; Zou, H.; Dang, Q.; Xu, H.; Liu, L.; Zhang, Y.; Lv, J.; Li, H.; Zhou, Z.; Han, X. Biological and pharmacological roles of m6A modifications in cancer drug resistance. Mol. Cancer 2022, 21, 220. [Google Scholar] [CrossRef] [PubMed]
Wang, H.; Xu, B.; Shi, J. N6-methyladenosine METTL3 promotes the breast cancer progression via targeting Bcl-2. Gene 2020, 722, 144076. [Google Scholar] [CrossRef] [PubMed]
Ma, J.Z.; Yang, F.; Zhou, C.C.; Liu, F.; Yuan, J.H.; Wang, F.; Wang, T.T.; Xu, Q.G.; Zhou, W.P.; Sun, S.H. METTL14 Suppresses the Metastatic Potential of Hepatocellular Carcinoma by Modulating N6-Methyladenosine-Dependent Primary MicroRNA Processing. Hepatology 2016, 65, 529–543. [Google Scholar] [CrossRef] [PubMed]
Panneerdoss, S.; Eedunuri, V.K.; Yadav, P.; Timilsina, S.; Rajamanickam, S.; Viswanadhapalli, S.; Abdelfattah, N.; Onyeagucha, B.C.; Cui, X.; Lai, Z.; et al. Cross-talk among writers, readers, and erasers of m6A regulates cancer growth and progression. Sci. Adv. 2018, 4, eaar8263. [Google Scholar]
Qin, S.; Mao, Y.; Chen, X.; Xiao, J.; Qin, Y.; Zhao, L. The functional roles, cross-talk and clinical implications of m6A modification and circRNA in hepatocellular carcinoma. Int. J. Biol. Sci. 2021, 17, 3059. [Google Scholar] [CrossRef]
Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424. [Google Scholar] [CrossRef]
Gong, S.; Wang, S.; Shao, M. Mechanism of METTL14-mediated m6A modification in non-small cell lung cancer cell resistance to cisplatin. J. Mol. Med. 2022, 100, 1771–1785. [Google Scholar] [CrossRef]
Zhang, Y.; Liu, S.; Zhao, T.; Dang, C. METTL3-mediated m6A modification of Bcl-2 mRNA promotes non-small cell lung cancer progression. Oncol. Rep. 2021, 46, 163. [Google Scholar] [CrossRef]
Liu, C.; Ren, Q.; Deng, J.; Wang, S.; Ren, L. c-MYC/METTL3/LINC01006 positive feedback loop promotes migration, invasion and proliferation of non-small cell lung cancer. Biomed. J. 2024, 47, 100664. [Google Scholar] [CrossRef] [PubMed]
Zhang, D.; Ning, J.; Okon, I.; Zheng, X.; Satyanarayana, G.; Song, P.; Xu, S.; Zou, M.H. Suppression of m6A mRNA modification by DNA hypermethylated ALKBH5 aggravates the oncological behavior of KRAS mutation/LKB1 loss lung cancer. Cell Death Dis. 2021, 12, 518. [Google Scholar] [CrossRef] [PubMed]
Xu, X.; Qiu, S.; Zeng, B.; Huang, Y.; Wang, X.; Li, F.; Yang, Y.; Cao, L.; Zhang, X.; Wang, J.; et al. N6-methyladenosine demethyltransferase FTO mediated m6A modification of estrogen receptor alpha in non-small cell lung cancer tumorigenesis. Oncogene 2024, 43, 1288–1302. [Google Scholar] [CrossRef] [PubMed]
Sun, Y.; Shen, W.; Hu, S.; Lyu, Q.; Wang, Q.; Wei, T.; Zhu, W.; Zhang, J. METTL3 promotes chemoresistance in small cell lung cancer by inducing mitophagy. J. Exp. Clin. Cancer Res. 2023, 42, 65. [Google Scholar] [CrossRef]
Sharba, M. M., Mohammed, A. A., & Mohammed, S. F. (2022). Isolation and Characterization of tannase from isolated Bacillus subtilis. [Google Scholar].
Zhang, S.; Dou, T.; Li, H.; Yu, H.; Zhang, W.; Sun, L.; Yang, J.; Wang, Z.; Yang, H. Knockdown of IGF2BP2 overcomes cisplatin-resistance in lung cancer through downregulating Spon2 gene. Hereditas 2024, 161, 55. [Google Scholar] [CrossRef]
Wang, X.; Kong, W.; Guo, F.; Sha, R.; Zhao, G.; Qiao, W.; Xu, K.; Feng, Y.; Sun, W.; Ma, X. Identification of Therapeutic Targets and Prognostic Biomarkers of IGF2BPs in the Lung Cancer Microenvironment. Sci. Rep. 2021, 15, 5681. [Google Scholar] [CrossRef]
Yu, M.; Ji, W.; Yang, X.; Tian, K.; Ma, X.; Yu, S.; Chen, L.; Zhao, X. The role of m6A demethylases in lung cancer: Diagnostic and therapeutic implications. Front. Immunol. 2023, 14, 1279735. [Google Scholar] [CrossRef]
Wan, W.; Ao, X.; Chen, Q.; Yu, Y.; Ao, L.; Xing, W.; Guo, W.; Wu, X.; Pu, C.; Hu, X.; et al. METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N6-methyladenosine modification of PD-L1 mRNA in breast cancer. Mol. Cancer 2022, 21, 60. [Google Scholar] [CrossRef]
Zhao, C.; Ling, X.; Xia, Y.; Yan, B.; Guan, Q. The m6A methyltransferase METTL3 controls epithelial-mesenchymal transition, migration and invasion of breast cancer through the MALAT1/miR-26b/HMGA2 axis. Cancer Cell Int. 2021, 21, 441. [Google Scholar] [CrossRef]
Pan, X.; Hong, X.; Li, S.; Meng, P.; Xiao, F. METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m6A-dependent manner. Exp. Mol. Med. 2021, 53, 91–102. [Google Scholar] [CrossRef]
Shi, Y.; Zheng, C.; Jin, Y.; Bao, B.; Wang, D.; Hou, K.; Feng, J.; Tang, S.; Qu, X.; Liu, Y.; et al. Reduced Expression of METTL3 Promotes Metastasis of Triple-Negative Breast Cancer by m6A Methylation-Mediated COL3A1 Up-Regulation. Front. Oncol. 2020, 10, 1126. [Google Scholar] [CrossRef]
Wang, S.; Zou, X.; Chen, Y.; Cho, W.C.; Zhou, X. Effect of N6-Methyladenosine Regulators on Progression and Prognosis of Triple-Negative Breast Cancer. Front. Genet. 2021, 11, 580036. [Google Scholar] [CrossRef]
Zhang, C.; Samanta, D.; Lu, H.; Bullen, J.W.; Zhang, H.; Chen, I.; He, X.; Semenza, G.L. Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m6A-demethylation of NANOG mRNA. Proc. Natl. Acad. Sci. USA 2016, 113, E2047–E2056. [Google Scholar] [CrossRef]
Malek, G. K., Hussein, S. A. M., & Mohammed, A. A. (2024). Effect of Puberty and Gender on Metabolic Hormones Level and Lipid Profile in Patients with Growth Hormone Deficiency. International Journal of Medical Science and Dental Health, 11(11), 63-72.[Google Scholar].
Chang, G.; Shi, L.; Ye, Y.; Shi, H.; Zeng, L.; Tiwary, S.; Huse, J.T.; Huo, L.; Ma, L.; Ma, Y.; et al. YTHDF3 Induces the Translation of m6A-Enriched Gene Transcripts to Promote Breast Cancer Brain Metastasis. Cancer Cell 2020, 38, 857–871.e7. [Google Scholar] [CrossRef] [PubMed]
Gong, P.J.; Shao, Y.C.; Yang, Y.; Song, W.J.; He, X.; Zeng, Y.F.; Huang, S.R.; Wei, L.; Zhang, J.W. Analysis of N6-Methyladenosine Methyltransferase Reveals METTL14 and ZC3H13 as Tumor Suppressor Genes in Breast Cancer. Front. Oncol. 2020, 10, 578963. [Google Scholar] [CrossRef] [PubMed]
Bai, X.; Liu, J.; Zhou, S.; Wu, L.; Feng, X.; Zhang, P. METTL14 suppresses the expression of YAP1 and the stemness of triple-negative breast cancer. J. Exp. Clin. Cancer Res. 2024, 43, 307. [Google Scholar] [CrossRef]
Schadendorf, D.; Fisher, D.E.; Garbe, C.; Gershenwald, J.E.; Grob, J.J.; Halpern, A.; Herlyn, M.; Marchetti, M.A.; McArthur, G.; Ribas, A.; et al. Melanoma. Nat. Rev. Dis. Prim. 2015, 1, 15003. [Google Scholar] [CrossRef]
O’Neill, C.H.; Scoggins, C.R. Melanoma. J. Surg. Oncol. 2019, 120, 873–881. [Google Scholar] [CrossRef]
Dahal, U.; Le, K.; Gupta, M. RNA m6A methyltransferase METTL3 regulates invasiveness of melanoma cells by matrix metallopeptidase 2. Melanoma Res. 2019, 29, 382–389. [Google Scholar] [CrossRef]
Yue, Z.; Cao, M.; Hong, A.; Zhang, Q.; Zhang, G.; Jin, Z.; Zhao, L.; Wang, Q.; Fang, F.; Wang, Y.; et al. m6A Methyltransferase METTL3 Promotes the Progression of Primary Acral Melanoma via Mediating TXNDC5 Methylation. Front. Oncol. 2022, 11, 770325. [Google Scholar] [CrossRef] [PubMed]
Wu, H.; Xu, H.; Jia, D.; Li, T.; Xia, L. METTL3-induced UCK2 m6A hypermethylation promotes melanoma cancer cell metastasis via the WNT/β-catenin pathway. Ann. Transl. Med. 2021, 9, 1155. [Google Scholar] [CrossRef] [PubMed]
Li, N.; Kang, Y.; Wang, L.; Huff, S.; Tang, R.; Hui, H.; Agrawal, K.; Gonzalez, G.M.; Wang, Y.; Patel, S.P.; et al. ALKBH5 regulates anti-PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment. Proc. Natl. Acad. Sci. USA 2020, 117, 20159–20170. [Google Scholar] [CrossRef]
Mohammed, A. A., Barale, S. S., Dhotare, P. S., & Sonawane, K. D. (2025). Polymyxin-B as a novel inhibitor of amyloid beta aggregation: Computational insights and experimental validation. Journal of Molecular Structure, 143738. [Google Scholar].
Jia, R.; Chai, P.; Wang, S.; Sun, B.; Xu, Y.; Yang, Y.; Ge, S.; Jia, R.; Yang, Y.G.; Fan, X. M6A modification suppresses ocular melanoma through modulating HINT2 mRNA translation. Mol. Cancer 2019, 18, 161. [Google Scholar] [CrossRef]
Ozakyol, A. Global Epidemiology of Hepatocellular Carcinoma (HCC Epidemiology). J. Gastrointest. Cancer 2017, 48, 238–240. [Google Scholar] [CrossRef]
Chen, M.; Wei, L.; Law, C.T.; Tsang, F.H.; Shen, J.; Cheng, C.L.; Tsang, L.H.; Ho, D.W.; Chiu, D.K.; Lee, J.M.; et al. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. Hepatology 2018, 67, 2254–2270. [Google Scholar] [CrossRef]
Lin, Y.; Wei, X.; Jian, Z.; Zhang, X. METTL3 expression is associated with glycolysis metabolism and sensitivity to glycolytic stress in hepatocellular carcinoma. Cancer Med. 2020, 9, 2859–2867. [Google Scholar] [CrossRef]
Qiao, K.; Liu, Y.; Xu, Z.; Zhang, H.; Zhang, H.; Zhang, C.; Chang, Z.; Lu, X.; Li, Z.; Luo, C.; et al. RNA m6A methylation promotes the formation of vasculogenic mimicry in hepatocellular carcinoma via Hippo pathway. Angiogenesis 2021, 24, 83–96. [Google Scholar] [CrossRef]
Chen, Y.; Zhao, Y.; Chen, J.; Peng, C.; Zhang, Y.; Tong, R.; Cheng, Q.; Yang, B.; Feng, X.; Lu, Y.; et al. ALKBH5 suppresses malignancy of hepatocellular carcinoma via m6A-guided epigenetic inhibition of LYPD1. Mol. Cancer 2020, 19, 123. [Google Scholar] [CrossRef]
Li, J.; Zhu, L.; Shi, Y.; Liu, J.; Lin, L.; Chen, X. M6A Demethylase FTO Promotes Hepatocellular Carcinoma Tumorigenesis via Mediating PKM2 Demethylation. Am. J. Transl. Res. 2019, 11, 6084. [Google Scholar] [PubMed]
Zhao, Y.; You, S.; Yu, Y.Q.; Zhang, S.; Li, P.T.; Ye, Y.H.; Zhao, W.X.; Li, J.; Li, Q.; Jiao, H.; et al. Decreased nuclear expression of FTO in human primary hepatocellular carcinoma is associated with poor prognosis. Int. J. Clin. Exp. Pathol. 2019, 12, 3376–3383. [Google Scholar] [PubMed]
Qin, S.; Liu, G.; Jin, H.; Chen, X.; He, J.; Xiao, J.; Qin, Y.; Mao, Y.; Zhao, L. The Comprehensive Expression and Functional Analysis of M6A Modification “Readers” in Hepatocellular Carcinoma. Aging 2022, 14, 6269. [Google Scholar] [CrossRef] [PubMed]
Aherkar, V. V., Mohammed, A. A., Al-Shimary, A. A., Kshirsagar, V., Shendage, R., Ubale, P. A., ... & Ovhal, R. M. (2025). Photocatalytic dye degradation efficacy and antimicrobial potency of zinc oxide nanoparticles synthesized via sol-gel method. Next Materials, 9, 100972. [Google Scholar]
Zhao, L.; Huang, H.; Luo, L.; Huang, Z.; Wu, Z.; Wang, F.; Wen, Z. The m6A reader IGF2BP3 promotes HCC progression by enhancing MCM10 stability. Sci. Rep. 2025, 15, 8204. [Google Scholar] [CrossRef]
Yao, Y.; Xie, J.; Ba, J.; Zhang, M.; Wan, Y.; Jin, Z. The m6A methyltransferase METTL3 promotes the stemness and malignant progression of breast cancer by mediating m6A modification on SOX2. JBUON 2021, 26, 444–449. [Google Scholar]
Chen, S.; Wang, L.; Xu, Z.; Chen, L.; Li, Q.; Zhong, F.; Tang, N.; Song, J.; Zhou, R. YTHDF3-mediated m6A modification of NKD1 regulates hepatocellular carcinoma invasion and metastasis by activating the WNT/β-catenin signaling axis. Exp. Cell Res. 2024, 442, 114192. [Google Scholar] [CrossRef]
Zhong, L.; Liao, D.; Zhang, M.; Zeng, C.; Li, X.; Zhang, R.; Ma, H.; Kang, T. YTHDF2 suppresses cell proliferation and growth via destabilizing the EGFR mRNA in hepatocellular carcinoma. Cancer Lett. 2019, 442, 252–261. [Google Scholar] [CrossRef]
Deng, X.; Qing, Y.; Horne, D.; Huang, H.; Chen, J. The roles and implications of RNA m6A modification in cancer. Nat. Rev. Clin. Oncol. 2023, 20, 507–526. [Google Scholar] [CrossRef]
Bedi, R.K.; Huang, D.; Eberle, S.A.; Wiedmer, L.; Śledź, P.; Caflisch, A. Small-Molecule Inhibitors of METTL3, the Major Human Epitranscriptomic Writer. ChemMedChem 2020, 15, 744–748. [Google Scholar] [CrossRef]
Yankova, E.; Blackaby, W.; Albertella, M.; Rak, J.; De Braekeleer, E.; Tsagkogeorga, G.; Pilka, E.S.; Aspris, D.; Leggate, D.; Hendrick, A.G.; et al. Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature 2021, 593, 597–601. [Google Scholar] [CrossRef]
Chen, W.; Zhang, J.; Ma, W.; Liu, N.; Wu, T. METTL3-Mediated m6A Modification Regulates the Polycomb Repressive Complex 1 Components BMI1 and RNF2 in Hepatocellular Carcinoma Cells. Mol. Cancer Res. 2025, 23, 190–201. [Google Scholar] [CrossRef]
Cesaro, B.; Iaiza, A.; Piscopo, F.; Tarullo, M.; Cesari, E.; Rotili, D.; Mai, A.; Diana, A.; Londero, M.; Del Giacco, L.; et al. Enhancing sensitivity of triple-negative breast cancer to DNA-damaging therapy through chemical inhibition of the m6A methyltransferase METTL3. Cancer Commun. 2024, 44, 282–286. [Google Scholar] [CrossRef] [PubMed]
Khamees, H. H., Mohammed, A. A., Hussein, S. A. M., Ahmed, M. A., & Raoof, A. S. M. (2024). In-Silico Study OF Destabilizing Alzheimer's Aβ42 Protofibrils with Curcumin. International Journal of Medical Science and Dental Health, 10(05), 76-84. [Google Scholar]
Huang, Y.; Su, R.; Sheng, Y.; Dong, L.; Dong, Z.; Xu, H.; Ni, T.; Zhang, Z.S.; Zhang, T.; Li, C.; et al. Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia. Cancer Cell 2019, 35, 677–691.e10. [Google Scholar] [CrossRef] [PubMed]
Su, R.; Dong, L.; Li, Y.; Gao, M.; Han, L.; Wunderlich, M.; Deng, X.; Li, H.; Huang, Y.; Gao, L.; et al. Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion. Cancer Cell 2020, 38, 79–96.e11. [Google Scholar] [CrossRef]
Lai, G.Q.; Li, Y.; Zhu, H.; Zhang, T.; Gao, J.; Zhou, H.; Yang, Z.-G. A covalent compound selectively inhibits RNA demethylase ALKBH5 rather than FTO. RSC Chem. Biol. 2024, 5, 335–343. [Google Scholar] [CrossRef]
Zhang, H.; Wang, X.; Chen, J.; Su, R. Combating cancer stem cells: RNA m6A methylation and small-molecule drug discovery. Front. Drug Discov. 2024, 4, 1465222. [Google Scholar] [CrossRef]
Moroz-Omori, E.V.; Huang, D.; Kumar Bedi, R.; Cheriyamkunnel, S.J.; Bochenkova, E.; Dolbois, A.; Rzeczkowski, M.D.; Li, Y.; Wiedmer, L.; Caflisch, A. METTL3 Inhibitors for Epitranscriptomic Modulation of Cellular Processes. ChemMedChem 2021, 16, 3035–3043. [Google Scholar] [CrossRef]
Dolbois, A.; Bedi, R.K.; Bochenkova, E.; Müller, A.; Moroz-Omori, E.V.; Huang, D.; Caflisch, A. 1,4,9-Triazaspiro[5.5]undecan-2-one Derivatives as Potent and Selective METTL3 Inhibitors. J. Med. Chem. 2021, 64, 12738–12760. [Google Scholar] [CrossRef] [PubMed]
